- Home
- VEL vs IVA Comparison
VEL vs IVA Comparison
Compare VEL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | IVA |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.4M | 769.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VEL | IVA |
|---|---|---|
| Price | $19.62 | $4.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $21.75 | $17.14 |
| AVG Volume (30 Days) | 59.9K | ★ 182.3K |
| Earning Date | 11-06-2025 | 09-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $229,360,000.00 | $19,929,536.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $27.31 | N/A |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | ★ 116.81 | N/A |
| 52 Week Low | $16.12 | $2.11 |
| 52 Week High | $20.98 | $7.98 |
Technical Indicators
Market Signals| Indicator | VEL | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 53.96 |
| Support Level | $18.53 | $4.05 |
| Resistance Level | $19.99 | $4.61 |
| Average True Range (ATR) | 0.63 | 0.20 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 88.24 | 86.92 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.